FERMT2 and central nervous system cancer: Recent studies have linked Kindlin-2 to tumor progression and Kindlin-2 upregulation was found in multiple malignancies including gastric cancer, bladder cancer, large cell lung carcinoma, esophageal squamous cell carcinoma, pancreatic ductal adenocarcinoma, clear cell renal carcinoma, malignant mesothelioma and glioma [9–18].